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Abstract
Background: Ghrelin, a gastric orexigenic peptide, and body mass index (BMI) are known as inversely associated to
each other and are both linked to cardiovascular (CV) risk and mortality in maintenance hemodialysis (MHD) patients.
However, it is unclear whether the interaction between ghrelin and BMI is associated with a risk of all-cause and CV
death in this population.
Methods: A prospective observational study was performed on 261 MHD outpatients (39% women, mean age
68.6 ± 13.6 years) recruited from October 2010 through April 2012, and were followed until November 2014
(median follow-up-28 months, interquartile range-19–34 months). We measured acyl-ghrelin (AG) levels,
appetite, nutritional and inflammatory markers, prospective all-cause and cardiovascular (CV) mortality.
Results: During follow-up, 109 patients died, 51 due to CV causes. A significant interaction effect of high BMI
and high AG (defined as levels higher than median) on all-cause mortality was found. Crude Cox HR for the
product termed BMI x AG was 0.52, with a 95% confidence interval (CI): 0.29 to 0.95 (P = 0.03). Evaluating the
interaction on an additive scale revealed that the combined predictive value of BMI and AG is larger than the
sum of their individual predictive values (synergy index was 1.1). Across the four BMI-AG categories, the group with
high BMI and high AG exhibited better all-cause and cardiovascular mortality irrespective of appetite and nutritional
status (multivariable adjusted hazard ratios were 0.31, 95% CI 0.16 to 0.62, P = 0.001, and 0.35, 95% CI 0.13 to 0.91, P = 0.
03, respectively). Data analyses made by dividing patients according to fat mass-AG, but not to lean body mass-AG
categories, provided similar results.
Conclusions: Higher AG levels enhance the favourable association between high BMI and survival in MHD patients
irrespective of appetite, nutritional status and inflammation.
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Background
An inverse association between body mass index (BMI)
and mortality, named the obesity paradox, has been
established in different populations including mainten-
ance hemodialysis (MHD) patients [1, 2]. Suggested rea-
sons for this effect have been published and discussed
elsewhere [2]. One reason given is better nutrition and
as a result better short-term survival of MHD patients
with higher BMI [2]. Among the factors contributing to
the regulation of food intake, energy homeostasis and
consequently to the regulation of body composition,
ghrelin, predominantly a stomach-derived, 28-amino acid,
orexigenic peptide, has a significant role [3, 4]. There are
two major molecular forms of plasma ghrelin: acylated
ghrelin (AG), with an n-octanoylated serine residue in
position 3, and des-acyl ghrelin (DAG) [5]. AG accounts
for about 10% of the total circulating ghrelin. In addition
to its orexigenic properties, ghrelin has a multiplicity of
physiological functions, affecting energy and glucose
homeostasis, gastrointestinal, cardiovascular, pulmonary
* Correspondence: iliab@asaf.health.gov.il
1Nephrology Division, Assaf Harofeh Medical Center, Zerifin. Affiliated with
the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Beberashvili et al. BMC Nephrology  (2017) 18:29 
DOI 10.1186/s12882-017-0442-8
and immune functions, cell proliferation and differenti-
ation, and bone physiology [6].
Although two to threefold higher plasma ghrelin levels
in end-stage kidney disease (ESKD) patients have been re-
ported in some studies, mainly on account of DAG [7, 8],
conflicting results have been presented by others [9]. In
this population, low plasma AG has demonstrated a
significant association with cardiovascular morbidity [10]
and low total ghrelin has been associated with all-cause
and cardiovascular mortality risks, especially when consid-
ered in conjunction with nutritional status, inflammation
and other weight-regulating hormones, such as leptin
[11]. Ghrelin concentrations in MHD patients, like as in
general population [12, 13], are inversely associated with
body mass index and truncal fat mass [8]. Therefore,
obese MHD patients with apparently a better prognosis
[1, 2] will more likely have low concentrations of ghrelin
which supposedly represent a poor prognosis in the same
population [10, 11]. It is not at all clear if MHD patients
with high BMI and high ghrelin levels will benefit more in
terms of clinical outcome than MHD patients with high
BMI and low ghrelin levels.
Therefore, the aim of this study is to investigate the
interaction of AG with BMI for predicting all-cause and
cardiovascular mortality in a cohort of MHD patients.
Methods
Patients
We have performed the prospective observational study.
The study was approved by the local Ethics Committee
(Assaf Harofeh Medical Center, Zerifin, affiliated with
the Sackler Faculty of Medicine, Tel Aviv University,
Israel). The study included MHD patients on hemodialysis
treatment for at least 8 weeks, who were 18 years or older,
and signed a local institutional review board-approved
consent form. Patients with an anticipated life expectancy
less than 6 months (e.g., because of a metastatic malig-
nancy) were excluded. In total, 261 patients undergoing
MHD treatment at our outpatient HD clinic and at two
satellite HD clinics (from the same region), were included
in the study. All patients underwent regular dialysis via
their vascular access (58.2% of patients had arterio-venous
fistula and 15.7%-arterio-venous grafts) 4 h three times per
week at a blood flow rate of 250–300 ml/min and at a dia-
lysis solution flow rate of 500 ml/min. The study popula-
tion has been described in more detail in a recent
publication [14]. In this same patient cohort, we observed
an association between serum uric acid with various
nutritional markers, muscle function, inflammation,
health-related QoL and clinical outcomes. The pa-
tients were recruited from October 2010 through
April 2012, and were followed until November 2014
or were censored (kidney transplantation or loss to
follow-up). The median duration of the study was
28 months (interquartile range 19.0–34.0 months).
Dietary intake and appetite assessment
The patients completed 3-day dietary histories (includ-
ing a dialysis day, a weekend day and a non-dialysis day)
as a food diary. Relying on these diaries the dietary en-
ergy and protein intake were calculated and normalized
for ideal body weight according to the European best
practice guidelines [15]. Ideal weight in the present
study was calculated from the Lorentz equations differ-
ently for men and women. Dietary intake was calculated
using computerized analysis (DOS-based program
“MANA,” specially adapted for data entry and analysis
of food intake records) [16].
Dietary protein intake was also approximated by deter-
mining normalized protein nitrogen appearance (nPNA)
from the patient’s urea generation rate by using urea
kinetics modeling [17]. Single-pool model urea kinetics
was used to estimate the nPNA.
With respect to the self-reported appetite assessment,
all patients were asked to grade their appetite during the
past week according to a 5-point Likert scale: 1) very
good, 2) good, 3) fair, 4) poor, and 5) very poor. These
questionnaires were completed when blood samples
were collected. The score was rearranged into two main
groupings for further comparisons: diminished (combining
fair, poor and very poor appetites) and non-diminished
(combining very good and good appetites).
Anthropometric measurements and handgrip strength
The following anthropometric variables were measured:
BMI, triceps skinfold thickness (TSF), mid arm cir-
cumference (MAC), and calculated mid arm muscle
circumference (MAMC).
The patients performed handgrip strength (HGS) in
both the dominant and non-dominant arms using the
Harpenden Handgrip Dynamometer (Yamar, Jackson,
MI, USA). HGS was repeated three times and the high-
est value was noted.
Nutritional scores
Overall nutritional assessment was performed using the
malnutrition-inflammation score (MIS) [18] and the
geriatric nutritional risk index (GNRI). GNRI was calcu-
lated using the equation developed by Bouillanne et al.
[19] and modifying it by the nutritional risk index for
elderly patients.
Body composition analysis
Body composition was established by using body imped-
ance analysis (B.I.A. Nutriguard-M, Data-Input, Frankfurt,
Germany). We performed BIA within a half an hour
post-dialysis according to the clinical application
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recommendations for analysis of bioelectrical impedance
[20]. The multi-frequency technique (using 3 frequencies:
5, 50 and 100 kHz) were used to estimate the total body
water (TBW), extracellular water (ECW), fat mass (FM)
and lean body mass (LBM). These estimates were ob-
tained using the NutriPlus software, version 5.1 (Data
Input GmbH, Germany).
Comorbidity index and clinical outcomes
We calculated the comorbidity index, developed recently
by Liu et al. [21] and validated specifically for dialysis pa-
tient populations, as a measure of comorbid conditions.
Cardiovascular mortality was defined as death result-
ing from coronary heart disease, sudden death, stroke,
or complicated peripheral vascular disease. Survival was
determined from the day of examination.
Laboratory evaluation
Predialysis blood samples and postdialysis serum urea
nitrogen were obtained from non-fasting patients on a
mid-week day. All biochemical analyses were measured
by an automatic analyzer. Additionally, serum high sen-
sitivity C-reactive protein (CRP) was measured by a tur-
bidimetric immunoassay. AG, IL-6 and TNF-α levels
were measured in plasma samples using commercially
available enzyme-linked immunosorbent assay (ELISA)
kits (R&D System, Minneapolis, MN, USA) according to
the manufacturer’s protocol.
Statistical analysis
Data are expressed as mean ± standard deviation (SD),
or as median with interquartile range (IQR) for variables
that did not follow a normal distribution, or as frequen-
cies for categorical data.
To measure the differences between the variables in
groups cross-classified by BMI and AG, a two-factor
MANOVA with Wilks-lambda was used. Since the dialy-
sis vintage, co-morbidity index, handgrip strength, CRP,
IL-6 and TNF-α levels were not normally distributed,
these variables were log transformed (lg10) before they
were inserted into this model.
Survival analyses were performed using the Kaplan-
Meier survival curve and the Cox proportional hazard
model. The univariate and multivariate Cox regression
analyses are presented as (HR; CI).
The interaction analyses between BMI and AG for
predicting all-cause and cardiovascular mortality were
investigated by Cox regression by simultaneously includ-
ing into the multiple regression models BMI, AG and
BMI x AG (BMI-based model). Other models to exam-
ine interactions between AG and fat mass, lean body
mass, TSF and MAMC assembled in a similar manner.
Interaction (synergism) between BMI and AG was de-
fined as a deviation from additivity occurring when the
observed hazard ratio (HR) for study outcomes of pa-
tients with both high BMI and high AG was higher than
that expected by summing up the hazard ratio of those
with high BMI and low AG or low BMI and high AG
minus one [22].
All statistical analyses were performed using SPSS
software, version 16.0 (SPSS Inc, Chicago, IL).
Results
For 261 MHD patients at the start of the cohort, the
median level of serum AG was 128.5 pg/ml, with IQR,
70.6 to 221.2 pg/ml. In our population, AG was inversely
associated with BMI (r = −0.25, p < 0.001) and with waist
circumference (r = −0.16, p = 0.03), as expected. To study
the interactions between AG and BMI on clinical out-
comes in our cohort, the patients were grouped accord-
ing to AG and BMI levels. High and low concentrations
were established according to median BMI and AG
levels and cross-classified. The clinical and biochemical
characteristics of the patients according to this categorization
are detailed in Table 1. Patients with high AG levels had
higher Kt/V and lower GNRI compared with the low AG
group. Patients with high BMI had lower Kt/v and MIS,
higher prevalence of DM, higher levels of albumin, creatinine,
uric acid, body composition indicators (both, anthropometric
and BIA derived) and GNRI, and fewer men and smokers
were in this group than in the low BMI group. Significant
BMI x AG interactions were found for gender, DM and serum
cholesterol levels. Consequently, these variables were included
in all further multivariable models. No statistically significant
differences were evident between the groups in the use of
medications (data not shown).
We measured the prognostic value of AG combined
with higher or lower BMI as well as with higher or lower
levels of surrogate measures of body composition
(Table 2). Both BMI and AG were significant predictors
of all-cause mortality in adjusted models. A statistical
interaction analysis showed a departure from a multipli-
city of effects of high BMI (above the median) with high
AG (above the median) levels. Crude Cox hazard ratio
for all-cause mortality for the product termed BMI x AG
was 0.52 with a 95% CI of 0.29 to 0.95 (P = 0.03). The
hazard ratio for all-cause mortality remained significant
after adjustments for age, sex, DM status, dialysis vintage
co-morbidity index, smoking, Kt/V, cholesterol and IL-6.
Interaction analyses carried out by stratifying patients
according to fat mass-AG and TSF-AG, but not to lean
body mass-AG, MAMC-AG or creatinine-AG categor-
ies, provided similar results (Table 2). No statistically
significant interactions were observed between AG and
body composition surrogate measures including BMI in
predicting hazards for cardiovascular death.
In addition to the multiplicative scale, we assessed the
aforementioned interaction on an additive scale to verify
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Table 1 Clinical and biochemical characteristics of 261 prevalent hemodialysis patients, grouped according to BMI and ghrelin levelsa
Low BMI (n = 131) High BMI (n = 130)
Low AG (n = 51) High AG (n = 80) Low AG (n = 78) High AG (n = 52) MANOVAb
Clinical characteristics
Age (years) 70.4 ± 14.8 67.9 ± 16.5 67.5 ± 10.9 69.8 ± 11.5 NS
Gender (men/women)c 80.4/19.6 60.3/39.7 57.5/42.5 50.0/50.0 B, B x AG
Log vintage (months) 1.26 ± 0.41 1.36 ± 0.40 1.19 ± 0.31 1.32 ± 0.35 NS
DM (yes)c 54.9 43.6 80.0 53.8 B, B x AG
Log comorbidity index 0.56 ± 0.33 0.55 ± 0.34 0.54 ± 0.34 0.47 ± 0.34 NS
Systolic BP (mm Hg) 142.0 ± 21.2 135.4 ± 27.8 140.6 ± 26.8 167.5 ± 87.2 NS
Diastolic BP (mm Hg) 65.0 ± 13.8 65.9 ± 13.8 66.5 ± 13.6 66.6 ± 12.9 NS
Kt/V 1.30 ± 0.25 1.44 ± 0.30 1.24 ± 0.31 1.32 ± 0.32 B, AG
Smoking (yes)c 19.6 20.5 6.3 9.6 B
Log handgrip strength (kg) 1.23 ± 0.31 1.21 ± 0.41 1.24 ± 0.35 1.20 ± 0.30 NS
Appetite (diminished)c 43.1 49.4 37.5 48.1 NS
Dietary intake
DEI (kcal/kg/d) 23.9 ± 6.7 22.7 ± 6.0 24.2 ± 6.9 23.1 ± 4.9 NS
DPI (g/kg/d) 1.05 ± 0.31 1.02 ± 0.34 1.12 ± 0.32 1.11 ± 0.27 NS
nPNA (g/kg/d) 0.99 ± 0.27 1.03 ± 0.26 1.02 ± 0.22 1.07 ± 0.24 NS
Blood analysis
Albumin (g/L) 37.9 ± 3.2 36.7 ± 4.4 38.1 ± 2.9 38.6 ± 3.5 B
Transferrin (mg/dl) 164.2 ± 26.4 169.5 ± 41.9 171.6 ± 25.7 168.7 ± 26.0 NS
Creatinine (mg/dl) 7.07 ± 2.0 6. 93 ± 2.02 7.39 ± 2.40 8.20 ± 2.02 B
Cholesterol (mg/dl) 148.0 ± 37.5 142.5 ± 31.0 143.5 ± 36.0 157.4 ± 39.1 B x AG
Triglycerides (mg/dl) 135.5 (93.0–167.0) 103.0 (82.0–140.3) 151.0 (107.5–238.0) 151.5 (113.5-194.8) B, AG
Uric acid (mg/dl) 5.27 ± 0.86 5.52 ± 1.02 6.00 ± 1.20 6.23 ± 1.31 B
Hemoglobin (g/dl) 11.3 ± 1.2 10.9 ± 1.4 11.1 ± 1.1 10.8 ± 1.1 NS
Log TNF-α (pg/ml) 1.35 ± 0.42 1.35 ± 0.41 1.38 ± 0.39 1.35 ± 0.32 NS
Log CRP (mg/L) 0.76 ± 0.39 0.71 ± 0.47 0.80 ± 0.53 0.72 ± 0.59 NS
Log IL-6 (pg/ml) 0.97 ± 0.45 0.95 ± 0.53 1.01 ± 0.31 0.92 ± 0.37 NS
Anthropometric measurements
TSF (mm) 12.6 ± 4.4 12.3 ± 4.3 18.7 ± 6.6 18.5 ± 6.1 B
MAC (cm) 25.5 ± 2.9 25.4 ± 3.0 30.6 ± 3.4 30.4 ± 3.6 B
MAMC (cm) 21.6 ± 2.5 21.7 ± 2.7 24.6 ± 2.9 24.4 ± 4.2 B
WC (cm) 94.1 ± 8.9 93.1 ± 11.7 115.7 ± 12.0 113.0 ± 10.5 B
W/H 0.99 ± 0.07 0.97 ± 0.10 1.05 ± 0.08 1.04 ± 0.08 B
Bioimpedance analysis
ECW/TBW 0.37 ± 0.04 0.37 ± 0.07 0.42 ± 0.05 0.40 ± 0.05 B
FM (kg) 17.2 ± 5.3 16.7 ± 6.9 33. 8 ± 11.5 31.2 ± 8.3 B
LBM (kg) 45.7 ± 7.8 45.2 ± 9.1 54.1 ± 10.8 51.0 ± 9.8 B
Phase angle (o) 4.3 ± 1.0 4.6 ± 1.5 4.9 ± 1.4 4.8 ± 1.1 B
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that the combined predictive value of BMI and AG is
larger than the sum of their individual predictive values.
The excess risk for all-cause death caused by the inter-
action (synergy index) was 1.1 times higher than that
portended by high BMI and high AG in the absence of
an interaction (Fig. 1).
During the follow-up period (median-28 months), 109
patients died (19 deaths/100 person-years). Of the 52 pa-
tients in the high BMI-high AG group, 15 patients died
(28.8%) in contrast to 28 out of 51 patients (54.9%) that
died in the low BMI-low AG group (Table 3). Moreover,
only seven cardiovascular deaths (13.5%) occurred in the
high BMI-high AG group versus 15 cardiovascular
deaths (29.4%) out of 51 patients that comprised the low
BMI-low AG group. The association between BMI and
the incidence rate of all-cause and CV mortality was
closely dependent on AG categories (effect modification
of BMI by ghrelin), with the incidence rate of all-cause
and CV mortality being maximal in patients with lower
BMI and lower AG and minimal in patients with higher
BMI and higher AG (Fig. 2). Further data adjustment
did not substantially affect these results (Table 4). The
hazard for death of patients with higher BMI and AG
was 0.31 (95% CI: 0.16–0.62) for all-cause death and
0.35 (95% CI: 0.13–0.91) for cardiovascular death, after
multivariate adjustments.
Discussion
Our study provides evidence that MHD patients with
higher BMI combined with higher AG concentrations
have a diminished all-cause and cardiovascular-related
mortality risk. Since both ghrelin [10, 11] and BMI [1, 2]
are associated with survival in the same directions, it is
possible that the combination of high BMI and high AG
levels confers a decreased risk of mortality in MHD pa-
tients by their cumulative independent contributions to
mortality. To our knowledge, the association of inter-
action of BMI and AG levels with survival of HD pa-
tients has not been previously investigated.
As a biomarker for mortality in the ESKD population,
ghrelin has been described as associated with traditional
cardiovascular risk factors, inflammation, and PEW [23].
The existing experimental data based on rodent heart
failure models provides evidence to suggest that ghrelin
may lower the risk of mortality and improve cardiovas-
cular outcomes [24]. AG attenuates in vitro angiogenesis
induced by oxidized low-density lipoprotein in human
coronary artery endothelial cells [25]. Ghrelin also sup-
presses pressure overload-induced cardiac hypertrophy
[26], reverses endothelial dysfunction in patients with
metabolic syndrome by increasing nitric oxide produc-
tions and bioactivity [27], suppresses sympathetic activity
and attenuates left ventricular remodeling following
myocardial infarction in Sprague-Dawley rats [28]. In
clinical studies, lower ghrelin levels have been shown to
be independent predictors of acute ischemic stroke [29],
as well as markers of acute and early myocardial infarc-
tion recovery periods [30]. In the MHD population, low
plasma ghrelin has been linked to cardiovascular mor-
bidity [10] and all-cause and cardiovascular mortality
risks [11]. Lower all-cause and cardiovascular mortality
rates are attributable to overweight and obese MHD pa-
tients compared to MHD patients with lower BMI [2].
While these relationships can be modified by several fac-
tors such as inflammation [31] or serum creatinine [32],
the linear inverse relationship between BMI and mortal-
ity was found as robust across models including mar-
ginal structural model analyses [33]. It is possible that a
wide array of cardiovascular activities in both physio-
logical and pathophysiological states enable AG to en-
hance the positive association between high BMI and
better clinical outcomes in the MHD population. The
finding that the lowest percentage of cardiovascular
deaths during follow-up was in the high BMI-high AG
category, allows this assumption.
Interestingly, AG excess can contribute to obesity-
associated insulin resistance in metabolic syndrome in
general population [34]. The prevalence of metabolic
syndrome is high in ESKD patients [35]. Therefore, in
the investigation of underlying pathophysiology of BMI-
AG interaction, the association between AG and meta-
bolic syndrome should be considered. While not all
Table 1 Clinical and biochemical characteristics of 261 prevalent hemodialysis patients, grouped according to BMI and ghrelin levelsa
(Continued)
Nutritional scores
MIS 7.28 ± 3.06 7.88 ± 3.99 5.21 ± 2.91 5.53 ± 2.95 B
GNRI 100.8 ± 7.4 98.6 ± 9.1 117.9 ± 9.0 115.2 ± 9.1 B, AG
Abbreviations: AG Acyl-ghrelin, TNF-α Tumor necrosis factor α, DM Diabetes mellitus, BP Blood pressure, nPNA Normalized protein nitrogen appearance, IL-6
Interleukin-6, BMI Body mass index, WC Waist circumference, W/H Waist to hip ratio, ECW/TBW Extra-cellular water to total body water ratio, FM Fat mass, LBM Lean
body mass, MIS Malnutrition-inflammation score, GNRI Geriatric nutritional risk index
aThe low BMI or AG group was defined as BMI <26. 8 kg/m2 or Gh < 128.5 pg/ml - values below the medians of distribution
bTwo-factor MANOVA. Significant (P < 0.05) effects are given for BMI (B), acyl-ghrelin (AG), and the interaction BMI with acyl-ghrelin (B x AG)
Continuous variables that did not follow a normal distribution (dialysis vintage, co-morbidity index, handgrip strength, TNF-α, CRP, IL-6) were log-transformed
before their insertion into this model
cAssessed by χ2 test
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markers of the metabolic syndrome were measured in
our study, no statistically significant differences were
observed in BMI, waist circumference, blood pressure,
triglycerides and uric acid levels between the high BMI-
high AG group compared with the three other groups
categorized by BMI and AG. Furthermore, in view of the
high prevalence of DM in our population, we adjusted
for diabetes in all multivariable models used in our
study. These data allow us to rule out the association of
AG with metabolic syndrome as the basis of interaction
between AG and BMI observed in our population.
Table 2 Crude and multiple Cox regression analysis of body
composition surrogates, ghrelin and their interactions for
predicting all cause and cardiovascular mortality in the study
population (n = 261)
Crude Adjusteda
Variable HR 95% CI p HR 95% CI p
All-cause mortality
AG (>128.5 pg/ml) 0.73 0.50–1.07 0.10 0.67 0.45–1.00 0.05
BMI (>26.8 kg/m2) 0.62 0.42–-0.91 0.015 0.58 0.38–0.88 0.01
FM (>22.6 kg) 0.57 0.39–0.85 0.005 0.53 0.34–0.82 0.005
LBM (>48.7 kg) 0.83 0.56–1.23 0.35 0.88 0.54–1.42 0.59
Cre (>7.18 mg/dl) 0.50 0.34–0.73 <0.001 0.57 0.37–0.89 0.01
MAMC (>23.2 cm) 0.65 0.44–0.96 0.03 0.67 0.44–1.03 0.06
BMI*AGb 0.52 0.29–0.95 0.033 0.46 0.25–0.85 0.01
FM* AG 0.53 0.29–0.96 0.038 0.69 0.53–0.92 0.01
TSF* AG 0.42 0.23–0.78 0.006 0.61 0.45–0.82 0.001
LBM* AG 0.95 0.56–1.62 0.85 0.86 0.65–1.13 0.27
Cr* AG 0.87 0.50–1.52 0.63 0.81 0.62–1.05 0.11
MAMC* AG 0.96 0.96–1.02 0.45 0.79 0.58–1.06 0.12
Cardiovascular mortality
AG (>128.5 pg/ml) 0.70 0.40–1.23 0.22 0.73 0.40–1.31 0.29
BMI (>26.8 kg/m2) 0.57 0.32–1.00 0.05 0.56 0.30–1.03 0.06
FM (>22.6 kg) 0.43 0.24–0.79 0.006 0.43 0.22–0.83 0.01
TSF (>14.0 mm) 0.62 0.35–1.07 0.09 0.76 0.40–1.44 0.39
LBM (>48.7 kg) 1.25 0.71–2.19 0.44 0.99 0.50–1.96 0.98
Cr (>7.18 mg/dl) 0.58 0.33–1.01 0.05 0.51 0.28–0.95 0.03
MAMC (>23.2 cm) 0.69 0.40–1.20 0.19 0.61 0.34–1.11 0.11
BMI* AGb 0.58 0.24–1.38 0.22 0.58 0.24–1.43 0.24
FM* AG 0.55 0.23–1.35 0.19 0.68 0.45–1.03 0.07
TSF* AG 0.59 0.26–1.38 0.23 0.73 0.50–1.08 0.12
LBM* AG 1.18 0.59–2.37 0.63 0.91 0.62–1.33 0.62
Cre* AG 0.67 0.30–1.47 0.31 0.68 0.46–1.01 0.06
MAMC* AG 0.69 0.31–1.55 0.37 0.66 0.43–1.01 0.06
Abbreviations: CI Confidence interval, HR Hazard ratio, AG Acyl-ghrelin, BMI
Body mass index, FM Fat mass, TSF Triceps skinfold, LBM Lean body mass, Cr
Creatinine, MAMC Midarm circumference calculated, DM Diabetes mellitus
aAdjusted for age, gender, DM status, dialysis vintage, comorbidity index,
smoking, Kt/V and cholesterol
bControlled for the main effects of variables included in interaction analysis
Fig. 1 Interaction between BMI and acyl-ghrelin (AG) (below or
above the corresponding median values) for explaining all-cause
mortality. The data are expressed as hazard ratios (HR) and 95%
confidence intervals (CI). The data are adjusted for age, sex, smoking,
diabetes, co-morbidity index, dialysis vintage, Kt/V, and cholesterol.
Deviation from additivity or the presence of interaction (synergism)
was assessed by comparing the observed joint effect of high ghrelin
and high BMI with that expected in the absence of interaction. The
expected effect of high ghrelin and high BMI in the absence of
interaction was calculated as HRHigh AG, Low BMI + HRLow AG, High BMI - 1
Table 3 Individual causes of death grouped according to BMI
and AG levelsa











5 1 2 1
Cerebrovascular
accident
3 2 3 1
Peripheral vascular
disease
4 3 2 1
Sudden death 1 6 4 1
Other cardiovascular 2 4 2 3
Infection/septicemia 6 13 6 7
Surgical peritonitis 1 1 3 -
Cancer 4 1 2 -
Other 2 6 5 1
All deathsb, n (%) 28 (54.9%) 37 (47.4%) 29 (36. 2%) 15 (28.8%)
CVD deathsb, n (%) 15 (29.4%) 16 (20.5%) 13 (16.2%) 7 (13.5%)
Abbreviations: CVD Cardiovascular disease, BMI Body mass index,
AG Acyl-ghrelin
aIndicated as the causes and number of deaths (n) in each category
bIndicated as the number of deaths and percentage, expressed as a proportion of
the total number of patients in the group. The proportion of deaths was higher
in the low BMI combined with low acyl-ghrelin group as assessed by χ2 test
(P < 0.001 for all deaths and CVD deaths)
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Ghrelin has potent anti-inflammatory effects [36–38]
that might play a role in the described interaction be-
tween BMI and AG on the clinical outcome of MHD
patients. The impact of chronic inflammation on the low
survival rate in the MHD population has been previously
documented [39, 40]. Ghrelin inhibits proinflammatory
cytokine release from T cells and monocytes [36], and
has been shown to suppress nuclear factor-κB activation
in human endothelial cells in vitro and endotoxin-
induced cytokine production in vivo [37]. In addition,
ghrelin treatment in a rat model of CKD has resulted in
a decrease of circulating inflammatory cytokines [38].
We however did not observe any statistically significant
differences in inflammatory markers measured in our
study across the four BMI-AG groups. Furthermore,
combined use of ghrelin and inflammatory markers (IL-6,
CRP) failed to explain the association between the meta-
bolic syndrome and the cardiovascular mortality in older
adults [41]. Taken together, the anti-inflammatory proper-
ties of ghrelin might be a factor but are probably not the
explanation for the interaction between BMI and AG on
survival rate in our study.
As an appetite-related hormone, high concentrations of
AG may contribute to a better nutritional status in MHD
patients, even in those with higher BMI. This could be a
potential explanation for our results. Certainly, while ele-
vated BMI characterizes a better nutritional condition
when compared to normal BMI [42] and accordingly,
improved survival rates [1, 2] in MHD patients, obese
sarcopenia was found to be associated with a poor prog-
nosis in this population [43]. It is possible that overweight
and obese ESKD patients with higher ghrelin are less likely
to present with PEW. DeBoer et al. [38] have shown that
ghrelin administration over a 2-week period increased
lean body mass retention in rats with cachexia associated
with CKD. Low total ghrelin levels have been related to
worsening nutritional status in a two-year follow-up
period in the elderly [44]. The statistically significant
increase in fat-free mass accompanied by improvements
in muscle strength has been shown in a two-year clinical
Table 4 Crude and adjusteda all-cause and CVD-related mortality grouped according to BMI and ghrelin levelsb
Variable All-cause mortality Cardiovascular mortality
HR (95% CI) P HR (95% CI) P
Low BMI, low AG (n = 51) Crude 1.0 1.0
Adjusted 1.0c 1.0c
Low BMI, high AG (n = 80) Crude 0.72 (0.44–1.19) 0.20 0.58 (0.29–1.19) 0.14
Adjusted 0.71 (0.42–1.23) 0.23 0.64 (0.29–1.39) 0.26
High BMI, low AG (n = 78) Crude 0.64 (0.38–1.08) 0.10 0.52 (0.29–1.10) 0.09
Adjusted 0.63 (0.35–1.11) 0.11 0.51 (0.22–1.15) 0.10
High BMI, high AG (n = 52) Crude 0.36 (0.19–0.68) 0.002 0.33 (0.13–0.82) 0.02
Adjusted 0.31 (0.16–0.62) 0.001 0.35 (0.13–0.91) 0.03
Abbreviations: CI Confidence interval, HR Hazard ratio, CVD Cardiovascular disease in the past, BMI Body mass index, AG Acyl-ghrelin
aAdjusted for age, gender, DM status, dialysis vintage, co-morbidity index, smoking, Kt/V, cholesterol and IL-6
bThe low BMI or AG group was defined as BMI <26. 8 kg/m2 or Gh < 128.5 pg/ml - values below the medians of distribution
cThe group of patients who had low BMI (defined as BMI levels below median) and low acyl-ghrelin (defined as acyl-ghrelin levels below median) was used as a reference
Fig. 2 Interaction between BMI and acyl-ghrelin (AG) for explaining all-cause mortality (a) and CVD mortality (b). The patients are divided into
four groups according to the median values of AG and BMI. The data are crude (unadjusted) incidence rates of all-cause and CVD mortality.
Abbreviations: BMI, body mass index; CVD, cardiovascular disease
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trial of an oral ghrelin mimetic in healthy individuals [45].
Short-term AG administration results in a significant in-
crease in dietary intake in malnourished MHD [46] and
peritoneal dialysis [47] patients. Although BMI displayed
the previously described positive associations with nu-
tritional markers [42] in our cohort, no statistically
significant differences in nutritional characteristics,
including lean body mass, were observed in the high
BMI and high AG group compared with the three
other groups, categorized by BMI and AG. The only
nutritional marker that exhibited statistical significance in
terms of BMI and AG interactions was the serum choles-
terol concentration that was higher in the high BMI- high
AG group. However, this interaction wasn’t independent
and the inclusion of the cholesterol levels in multivariable
models didn’t influence the results of our study. In
addition, interaction analyses carried out on multiplicative
scale revealed no interaction for lean body mass, MAMC
or serum creatinine with AG on clinical prognosis of our
population. Furthermore, no statistically significant differ-
ences in appetite and consequently dietary intake between
the four BMI-AG groups were observed in our study. The
complexity of appetite regulation in MHD patients which
involves counter-regulatory signaling of orexigens (ghrelin,
neuropeptide Y) and anorexigens (leptin, peptide YY) [48]
may explain this finding. The lack of a statistical difference
in the nutritional parameters of the high BMI and high
AG group compared with the other BMI-AG categories
may suggest that the biological basis for statistical inter-
action between the fat mass and AG on the survival in our
study is the fat tissue’s property to secrete adipokines [49].
There are dual competing effects (protective - due to nu-
trition and deleterious - due to inflammatory adipokines)
of fat mass on survival in MHD patients [50]. We believe
that the favorable balance between the various pro- and
anti-inflammatory adipokines may enhance AGs’ effect on
clinical outcomes in MHD population with higher BMI,
presumably through modulating insulin resistance and the
cardiovascular effects of AG. This hypothesis should be
tested in future studies.
Our study has limitations that should be considered.
First, no definitive cause-and-effect relationship can be
derived for any of the analyzed risk factors. This limita-
tion is typical for observational approach study. Second,
we might have underestimated the cardiovascular deaths
proportion. This is because the cause of death was taken
from the patient records and was not postmortemly con-
firmed. Third, samples were taken in non-fasting condi-
tions, 1–3 h after a meal. It is difficult to obtain fasting
blood samples from patients with diabetes and patients
with an afternoon or night dialysis schedule. On the
other hand, AG levels were characterized by a blunted
premeal rise in dialysis patients [48] and less markedly
affected by the postprandial state when compared with
healthy controls [51]. Another limitation is assessment
of dietary intake by a 3 day food record, as results can
be subjective and incomplete. Our study did not have
detailed serum markers of oxidative stress, insulin resist-
ance or oxidized lipids, which could have provided
additional evidence to reinforce proposed mechanistic
pathways for our findings of strong associations. Finally,
AG measurements in our study didn’t account for the
parallel evaluation of some of the pro- and/or counter-
regulatory molecules to AG’s actions such as adipokines
that are also involved in appetite and body composition
regulation [49, 50]. Despite these limitations, the avail-
ability of extensive data of nutritional and inflammatory
biomarkers, body composition, comorbidities, and long-
term follow-up strengthens the study.
Conclusions
In conclusion, we report that higher AG levels enhance
the favorable association between high BMI and survival
in MHD patients irrespective of appetite, nutritional sta-
tus and inflammation. Apparently, the role of AG as a
cardiovascular marker contributes to this interaction.
While the potential clinical utility of AG therapy in
MHD patients in reversing PEW and associated worse
prognosis has been previously discussed [11], based on
the results of our study, overweight and obese MHD pa-
tients without PEW but with low AG levels, may also
benefit from ghrelin therapy to improve long-term out-
comes. The subcutaneous administration of 3.6 nmol/kg
AG once a day (according to the short-term studies per-
formed in healthy volunteers [52] and in MHD or PD
patients [46, 47]), given 1 h before a meal, presumably
for a period between 6 months to a year, may serve this
purpose. Concomitantly, the risks of developing ghrelin
resistance and its mitogenic potential should also be
considered [9].
Abbreviations
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